Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03309332 · ClinicalTrials.gov registry record · NA
AMPLATZER PFO Occluder Post Approval Study
A NA study of Stroke and Patent Foramen Ovale, sponsored by Abbott Medical Devices.
- Active
- Registry status
- NA
- Development phase
- 1,214
- Enrollment target
- 20
- Study locations
NCT03309332: Active NA study of Stroke and Patent Foramen Ovale, sponsored by Abbott Medical Devices.
NCT03309332 is a NA study of Stroke and Patent Foramen Ovale that is active but no longer recruiting, run by Abbott Medical Devices. The registered enrollment target is 1,214 participants, below the 12,014-participant average among 454 other Stroke trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03309332, a NA study of Stroke and Patent Foramen Ovale, is active but no longer recruiting, sponsored by Abbott Medical Devices.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 1,214 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this single arm, multi-center study is to confirm the safety and effectiveness of the AMPLATZER™ PFO Occluder in the post Approval Setting.
Primary Outcome
5 year rate of recurrent ischemic stroke
Conditions Studied
Interventions
- DEVICE AMPLATZER™ PFO Occluder
Study Locations (20)
California
- Kaiser Permanente Los Angeles Medical Center - Los Angeles
- USC University Hospital - Los Angeles
- Ronald Reagan UCLA Medical Center - Los Angeles
- Sutter Medical Center - Sacramento
- San Diego Cardiac Center - San Diego
- University of California at San Francisco - San Francisco
- Stanford University Medical Center - Stanford
- Los Robles Hospital and Medical Center - Thousand Oaks
Arizona
- Chandler Regional Medical Center - Chandler
- St. Joseph's Hospital and Medical Center - Phoenix
- Scottsdale Healthcare Shea - Scottsdale
- Pima Heart Physicians, PC - Tucson
Colorado
- University of Colorado Hospital - Aurora
- Memorial Hospital of Colorado Springs - Colorado Springs
- Denver Heart - Denver
- South Denver Cardiology Associates PC - Littleton
Alabama
- University of Alabama at Birmingham - Birmingham
- Heart Center Research, LLC - Huntsville
Arkansas
- UAMS Medical Center - Little Rock
District of Columbia
- MedStar Washington Hospital Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,214 participants |
| Start Date | 2018-01-31 |
| Est. Completion | 2030-02-05 |
| Phase | NA |
What the registry record for NCT03309332 still lists
NCT03309332 is an interventional study that assigns participants to a tested intervention. Its 1,214 participants enrollment target places it among the larger protocols in the corpus, below the 12,014-participant average among 454 other Stroke trials with a reported enrollment target (90% lower).
The record links to 2 conditions, with Stroke appearing as the primary indexed condition, and to 1 intervention - of which AMPLATZER™ PFO Occluder is the first listed.
NCT03309332 names 20 study sites across 6 states, led by California, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT03309332 about?
NCT03309332 is a clinical study titled "AMPLATZER PFO Occluder Post Approval Study". The purpose of this single arm, multi-center study is to confirm the safety and effectiveness of the AMPLATZER™ PFO Occluder in the post Approval Setting.
What is the current status of trial NCT03309332?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 1,214 participants. The study started on 2018-01-31. Estimated completion is 2030-02-05.
What conditions does trial NCT03309332 study?
This clinical trial studies the following conditions: Stroke, Patent Foramen Ovale.
What interventions are being tested in trial NCT03309332?
The interventions under investigation include: AMPLATZER™ PFO Occluder (DEVICE).
Who is sponsoring clinical trial NCT03309332?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03309332 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03309332's enrollment target sits among peer trials
1,214 34th of 454 higher than 421 of 454 other Stroke trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tracking a Tactile Signal Along the Nervous System
RECRUITING · NA
-
Transcranial Direct Current Stimulation (tDCS) With Verb Network Strengthening Treatment (VNeST) in Chronic Aphasia
RECRUITING · NA
-
Strategy Training for Individuals With Unilateral Neglect
RECRUITING · NA
-
Weight Loss and ExeRcise
RECRUITING · NA
-
Safety and Feasibility of an ExoNET for Supination Assistance for Stroke Survivors
RECRUITING · NA
-
Deep Brain Stimulation Motor Ventral Thalamus (VOP/VIM) for Restoration of Speech and Upper-limb Function in People With Subcortical Stroke
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05827016 · 1,216 participants · Phase 3
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
- NCT06143956 · 1,217 participants · Phase 2
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- NCT04267848 · 1,210 participants · Phase 3
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- NCT05946213 · 1,209 participants · Phase 3
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI